Harrow (HROW) Competitors $28.95 -1.18 (-3.92%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$29.36 +0.41 (+1.40%) As of 02/21/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HROW vs. PBH, BHVN, PTCT, OGN, RARE, RNA, AKRO, RYTM, APLS, and VKTXShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Prestige Consumer Healthcare (PBH), Biohaven (BHVN), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical preparations" industry. Harrow vs. Prestige Consumer Healthcare Biohaven PTC Therapeutics Organon & Co. Ultragenyx Pharmaceutical Avidity Biosciences Akero Therapeutics Rhythm Pharmaceuticals Apellis Pharmaceuticals Viking Therapeutics Harrow (NASDAQ:HROW) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Does the media prefer HROW or PBH? In the previous week, Prestige Consumer Healthcare had 3 more articles in the media than Harrow. MarketBeat recorded 5 mentions for Prestige Consumer Healthcare and 2 mentions for Harrow. Prestige Consumer Healthcare's average media sentiment score of 1.21 beat Harrow's score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prestige Consumer Healthcare 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in HROW or PBH? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 13.7% of Harrow shares are owned by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, HROW or PBH? Prestige Consumer Healthcare has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$130.19M7.92-$24.41M-$0.94-30.80Prestige Consumer Healthcare$1.13B3.73$209.34M$4.2719.83 Which has more risk and volatility, HROW or PBH? Harrow has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Does the MarketBeat Community prefer HROW or PBH? Prestige Consumer Healthcare received 405 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 70.51% of users gave Prestige Consumer Healthcare an outperform vote while only 58.82% of users gave Harrow an outperform vote. CompanyUnderperformOutperformHarrowOutperform Votes9058.82% Underperform Votes6341.18% Prestige Consumer HealthcareOutperform Votes49570.51% Underperform Votes20729.49% Is HROW or PBH more profitable? Prestige Consumer Healthcare has a net margin of 19.13% compared to Harrow's net margin of -19.75%. Prestige Consumer Healthcare's return on equity of 12.36% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-19.75% -45.57% -8.87% Prestige Consumer Healthcare 19.13%12.36%6.39% Do analysts recommend HROW or PBH? Harrow presently has a consensus target price of $61.50, suggesting a potential upside of 112.44%. Prestige Consumer Healthcare has a consensus target price of $92.60, suggesting a potential upside of 9.37%. Given Harrow's stronger consensus rating and higher possible upside, equities analysts plainly believe Harrow is more favorable than Prestige Consumer Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Prestige Consumer Healthcare 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryPrestige Consumer Healthcare beats Harrow on 11 of the 17 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.5616.5114.19Price / Sales7.92304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book14.406.717.644.63Net Income-$24.41M$138.11M$3.18B$245.69M7 Day Performance-4.83%-2.54%-1.95%-2.68%1 Month Performance-16.21%-2.00%-0.23%-2.16%1 Year Performance160.34%-5.04%16.69%12.90% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.282 of 5 stars$28.95-3.9%$61.50+112.4%+162.2%$1.07B$130.19M-30.80182PBHPrestige Consumer Healthcare3.9802 of 5 stars$85.62-0.1%$92.60+8.2%+22.2%$4.23B$1.13B20.05540Positive NewsBHVNBiohaven3.4013 of 5 stars$41.45-0.8%$63.15+52.4%-20.8%$4.19BN/A-4.43239Short Interest ↓Positive NewsPTCTPTC Therapeutics3.62 of 5 stars$51.82+4.3%$58.85+13.6%+95.4%$4.00B$937.82M-8.721,410Analyst ForecastNews CoverageOGNOrganon & Co.4.9279 of 5 stars$15.30-6.3%$20.80+36.0%-16.5%$3.94B$6.26B3.0310,000RAREUltragenyx Pharmaceutical4.617 of 5 stars$42.49-2.4%$92.43+117.5%-11.6%$3.92B$434.25M-6.571,276Analyst ForecastRNAAvidity Biosciences1.6172 of 5 stars$32.31-2.2%$65.80+103.7%+116.3%$3.85B$9.56M-11.22190AKROAkero Therapeutics4.4064 of 5 stars$50.52+2.6%$75.86+50.2%+115.6%$3.53BN/A-13.4730Insider TradeRYTMRhythm Pharmaceuticals4.0825 of 5 stars$56.69-1.5%$68.09+20.1%+14.9%$3.48B$77.43M-13.09140Analyst ForecastInsider TradeNews CoverageAPLSApellis Pharmaceuticals4.2246 of 5 stars$27.40-0.2%$46.71+70.5%-58.9%$3.41B$396.59M-13.50770Short Interest ↓VKTXViking Therapeutics4.3881 of 5 stars$30.48+3.3%$97.29+219.2%-3.2%$3.40BN/A-30.4820 Related Companies and Tools Related Companies Prestige Consumer Healthcare Alternatives Biohaven Alternatives PTC Therapeutics Alternatives Organon & Co. Alternatives Ultragenyx Pharmaceutical Alternatives Avidity Biosciences Alternatives Akero Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Viking Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HROW) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
